Skip to main content

Month: April 2022

Labrador Uranium Announces Upsize of Bought Deal Private Placement to C$8.0 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, April 11, 2022 (GLOBE NEWSWIRE) — Labrador Uranium Inc. (“LUR” or “Labrador Uranium”) (CSE: LUR) (F: EI1) is pleased to announce that due to significant investment demand, LUR has agreed to amend its agreement with Red Cloud Securities Inc., as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively, the “Underwriters”), to increase the size of LUR’s previously announced bought deal private placement from C$7.0 million to C$8.0 million. Under the revised offering, the Underwriters have agreed to purchase for resale 5,715,000 flow-through units of LUR to be sold to charitable purchasers (each, a “Charity FT Unit”) at a price of C$1.40 per Charity FT Unit (the “Unit Price”) on a “bought deal”...

Continue reading

DT Midstream Announces Closing of Private Offering of Senior Secured Notes

DETROIT, April 11, 2022 (GLOBE NEWSWIRE) — DT Midstream, Inc. (“DT Midstream” or the “Company”) (NYSE: DTM) today announced that it has closed the previously announced offering (the “Offering”) of $600,000,000 of 4.300% Senior Secured Notes due 2032 (the “Notes”). The Notes were issued by DT Midstream, guaranteed by certain of DT Midstream’s subsidiaries and secured by a first priority lien on certain assets of DT Midstream and its subsidiary guarantors that secure DT Midstream’s existing credit facilities. DT Midstream used the net proceeds from the sale of the Notes to partially repay existing indebtedness under its term loan facility and the transaction is leverage-neutral. The Notes were sold in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities...

Continue reading

Imprivata Acquires SecureLink to Deliver the Only Single-Vendor Platform to Manage and Secure All Enterprise and Third-Party Digital Identities

Imprivata will unlock further value for customers by unifying, integrating, and automating digital identity to enable autonomous identity systems WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) — Imprivata, the digital identity company for mission- and life-critical industries, today announced it has closed its acquisition of SecureLink, the leader in critical access management with elite patient privacy monitoring. The acquisition uniquely addresses the rapidly growing need for a single source to enable and protect all digital identities, spanning enterprise to third parties. According to CISA, stolen credentials are one of the primary attack vectors for gaining illegal access into networks, including access from supply chains and third-party vendors. In fact, third-party vendors account for 51% of data breaches. Together with...

Continue reading

Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results

DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal year 2021. Fiscal Year 2021 Results Total revenues for fiscal year 2021 were $93.0m compared to $102.0m in 2020, a decrease of 8.8% year on year and were broken down as follows:    Full Year2020 Full Year2021 Increase/(decrease)  US$’000 US$’000 %Point-of-Care 9,215 10,337 12.2%         Clinical Laboratory 92,765 82,628 (10.9%)         Total 101,980 92,965 (8.8%)  Point-of-Care revenues increased from $9.2m in 2020 to $10.3m in 2021, which represents an increase of 12.2%. This was driven by higher HIV sales in Africa. In 2020, HIV revenues...

Continue reading

EXL selected by HealthPartners to develop next-generation care management platform

EXL CareRadius™ delivers integrated population health analytics to identify at-risk patients, spot gaps in care and drive more streamlined care management NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a leading data analytics and digital operations and solutions company, today announced that it was selected by HealthPartners, the largest consumer-governed, non-profit health care organization in the nation, to develop a next-generation care management solution. Leveraging EXL’s CareRadiusTM platform, HealthPartners will now be able to incorporate powerful population health analytics directly into its care management workflow, delivering more targeted, timely and effective interventions and improved member engagement. “In order to deliver truly patient-centric, value-based care it is essential for us to be able...

Continue reading

HeartCore Launches Upgraded Corporate Content Management System

NEW YORK and TOKYO, April 11, 2022 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc., (“HeartCore” or “the Company”), a leading software development company, announced the launch of its revamped corporate digital marketing solution, Content Management System (“CMS”). The CMS is HeartCore’s customer experience management platform that streamlines website operations, allowing users to easily create, manage, and modify content on websites without the need for specialized technical knowledge. The upgraded version will allow users to realize headless distribution of diversified content and centralized management of increasing Product Information Management (“PIM”) and Digital Asset Management (“DAM”) as a hub for all content delivery, role-based management and editing functions. Additionally, users will now be able to manage prospects,...

Continue reading

Origis Energy Builds on Long-Term Alliance with Order for 750 MW of First Solar Modules

Modules slated for 2024 delivery; Origis to benefit from technology developments through agile contractingOrigis Energy Builds on Long-Term Alliance with Order for 750 MW of First Solar Modules First Solar, Inc. today announced that Origis Energy, one of America’s largest solar and energy storage developers, has placed an order for 750 megawatts (MW)DC of responsibly-produced thin film photovoltaic (PV) solar modules.TEMPE, Ariz., April 11, 2022 (GLOBE NEWSWIRE) — First Solar, Inc. (Nasdaq: FSLR) today announced that Origis Energy, one of America’s largest solar and energy storage developers, has placed an order for 750 megawatts (MW)DC of responsibly-produced thin film photovoltaic (PV) solar modules. The deal, which was booked prior to the release of First Solar’s Q4 and Full Year 2021 earnings in February, utilizes First...

Continue reading

Duck Creek Welcomes Jess Keeney as Chief Product Officer

Keeney joins the Executive Committee to lead Duck Creek’s product vision and strategy Boston, April 11, 2022 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT), a leading, global technology solutions provider to the property and casualty (P&C) insurance industry, today welcomes Jess Keeney to its leadership team as Chief Product Officer. In her role, Keeney will lead Duck Creek’s product vision to drive value for customers, partners and system integrators. Keeney joins Duck Creek as Chief Product Officer with 15 years of experience delivering B2B products at an enterprise scale across multiple industries. She previously worked at ZoomInfo Technologies Inc. (NASDAQ GS: ZI), a leading go-to-market intelligence platform, and UKG, a multinational technology company providing workforce and human resource management services,...

Continue reading

BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, April 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has been awarded a supplemental grant of approximately $100,000 by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) for the first-in-human clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary. BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002, “Development of Medications...

Continue reading

Milestone Scientific Commences Sales of CompuFlo® Epidural / CathCheck™ Verification System Disposables to a Premier Northeast Hospital

ROSELAND, N.J., April 11, 2022 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today reported that, following a successful trial and evaluation, it has commenced sales of its CompuFlo® Epidural and CathCheck™ Verification System disposables to a leading northeast medical center. The hospital has been designated as one of the World’s Best Hospitals-USA by Newsweek for the fourth consecutive year. “We are honored to announce adoption of our CompuFlo Epidural and CathCheck Verification System by another leading medical center,” commented Arjan Haverhals, CEO of Milestone Scientific. “This approval follows a thorough trial and evaluation, which further validates the safety and efficacy of our technology. As a teaching...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.